Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
107
datasets available to search
ShareScore release 0.9.0
Dataset results
107 results for βDrug exposureβ
OMOP2OBO Drug Exposure Ingredient Mappings
<p><strong>OMOP2OBO Drug Exposure Ingredient Mappings V1.0</strong></p> <p>These mappings were created by the OMOP2OBO mapping algorithm (see links below). OMOP2OBO - the first health system-wide, disease-agnostic mappings between standardized clinical terminologies and eight Open Biomedical Ontology (OBO) Foundry ontologies spanning diseases, phenotypes, anatomical entities, cell types, organisms, chemicals, vaccines, and proteins. These mappings are also the first to be explicitly created using standard terminologies in the Observational Medical Outcomes (OMOP) common data model (CDM), ensuring both semantic and clinical interoperability across a space of N conditions [and N relationships curated in these ontologies].</p> <p>The mappings in this repository were created between OMOP standard drug exposure concepts at the ingredient-level (i.e., RxNorm) to the Chemical Entities of Biological Interest (ChEBI), the National Center for Biotechnology Information Taxon Ontology (NCBITaxon), the Protein Ontology (PRO), and the Vaccine Ontology (VO). All concepts were aligned to at least one ChEBI concept and the remaining ontologies (NCBITaxon, PR, and VO) were mapped by their drug class and/or type (e.g., biologics versus vaccines). For these OMOP domains, owl:intersectionOf (“and”), and owl:unionOf (“or”) constructors were used to construct semantically expressive mappings.</p> <p><br> <strong>Mapping Details</strong><br> Mappings included in this set were generated automatically using OMOP2OBO or through the use of a Bag-of-words embedding model using TF-IDF. Cosine similarity is used to compute similarity scores between all pairwise combinations of OMOP and OBO concepts and ancestor concepts. To improve the efficiency of this process, the algorithm searches only the top π most similar results and keeps the top 75th percentile among all pairs with scores >= 0.25. Manually created mappings are also included.</p> <p><strong><em>Mapping Categories</em></strong></p> <ul> <li><strong>Automatic One-to-One Concept</strong>: Exact label or synonym, dbXRef, or expert validated mapping @ concept-level; 1:1</li> <li><strong>Automatic One-to-One Ancestor:</strong> Exact label or synonym, dbXRef, or expert validated mapping @ concept ancestor-level; 1:1</li> <li><strong>Automatic One-to-Many Concept: </strong>Exact label or synonym, dbXRef, cosine similarity, or expert validated mapping @ concept-level; 1:Many</li> <li><strong>Automatic One-to-Many Ancestor:</strong> Exact label or synonym, dbXRef, cosine similarity, or expert validated mapping @ concept-level; 1:Many</li> <li><strong>Manual One-to-One: </strong>Hand mapping created using expert suggested resources; 1:1</li> <li><strong>Manual One-to-Many:</strong> Hand mapping created using expert suggested resources; 1:Many</li> <li><strong>Cosine Similarity:</strong> score suggested mapping -- manually verified</li> <li><strong>UnMapped:</strong> No suitable mapping or not mapped type</li> </ul> <p><em><strong>Mapping Statistics</strong></em><br> Additional statistics have been provided for the mappings and are shown in the table below. This table presents the counts of OMOP concepts by mapping category and ontology:</p> <table align="center"> <thead> <tr> <th scope="col">Mapping category</th> <th scope="col">ChEBI</th> <th scope="col">NCBITaxon</th> <th scope="col">PRO</th> <th scope="col">VO</th> </tr> </thead> <tbody> <tr> <td>Automatic One-to-One Concept</td> <td>3151</td> <td>155</td> <td>43</td> <td>108</td> </tr> <tr> <td>Automatic One-to-Many Constructor</td> <td>404</td> <td>1</td> <td>1</td> <td>0</td> </tr> <tr> <td>Automatic One-to-One Ancestor</td> <td>147</td> <td>17</td> <td>20</td> <td>4</td> </tr> <tr> <td>Automatic One-to-Many Ancestor</td> <td>210</td> <td>3</td> <td>2</td> <td>2</td> </tr> <tr> <td>Cosine Similarity</td> <td>109</td> <td>4241</td> <td>18</td> <td>17</td> </tr> <tr> <td>Manual</td> <td>322</td> <td>230</td> <td>157</td> <td>21</td> </tr> <tr> <td>Manual One-to-Many</td> <td>72</td> <td>14</td> <td>8</td> <td>2</td> </tr> <tr> <td>UnMapped</td> <td>7392</td> <td>7146</td> <td>11558</td> <td>11653</td> </tr> </tbody> </table> <p><br> <strong>Provenance and Versioning: </strong>The V1.0 deposited mappings were created by OMOP2OBO v1.0.0 on October 2022 using the OMOP Common Data Model V5.0 and OBO Foundry ontologies downloaded on September 14, 2020. </p> <p><strong>Caveats:</strong> Please note that these are the original mappings that were created for the preprint. They have not been updated to current versions of the ontologies. In our experience, this should result in very few errors, but we do suggest that you check the ontology concepts used against current versions of each ontology before using them.</p> <p> </p> <p><strong>Important Resources and Documentation</strong></p> <ul> <li>GitHub: <a href="https://github.com/callahantiff/OMOP2OBO">OMOP2OBO</a></li> <li>Project Wiki: <a href="https://github.com/callahantiff/OMOP2OBO/wiki">OMOP2OBO - wiki</a></li> <li>Zenodo Community: <a href="https://zenodo.org/communities/omop2obo">OMOP2OBO</a></li> <li>Preprint Manuscript: <a href="https://doi.org/10.5281/zenodo.5716421">10.5281/zenodo.5716421</a></li> </ul>
Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
ClinicalTrials.gov study NCT03397108. IPD Sharing: YES. Countries: 1. Publications: 2.
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
ClinicalTrials.gov study NCT04207840. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Buprenorphine Pharmacometric Open Label Research Study of Drug Exposure
ClinicalTrials.gov study NCT03608696. IPD Sharing: YES. Countries: 1. Publications: 1.
Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy
ClinicalTrials.gov study NCT02012621. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
ClinicalTrials.gov study NCT02564471. IPD Sharing: NO. Countries: 1. Publications: 1.
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
ClinicalTrials.gov study NCT02263326. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
ClinicalTrials.gov study NCT01505114. IPD Sharing: Not stated. Countries: 2. Publications: 5.
Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women
ClinicalTrials.gov study NCT02584140. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Data from: Risks of 23 specific malformations associated with prenatal exposure to ten antiepileptic drugs
Objective: To assess the association between exposure to monotherapy with 10 different antiepileptic drugs (AED) during the first two months of pregnancy and the risk of 23 major congenital malformations (MCMs). Methods: This nationwide cohort study, based on the French healthcare databases, included all pregnancies&[ge]20 weeks and ending between January 2011 and March 2015. Women were considered to be exposed when an AED had been dispensed between one month before and two months after the beginning of pregnancy. The reference group included pregnant women with no reimbursement for AEDs. MCMs were detected up to 12 months after birth (24 months for microcephaly, hypospadias and epispadias). Odds ratios were adjusted for potential confounders for MCMs with at least five cases. Otherwise, we calculated crude ORs with exact confidence intervals. Results: The cohort included 1,886,825 pregnancies, 2,997 of which were exposed to lamotrigine, 1,671 to pregabalin, 980 to clonazepam, 913 to valproic acid, 579 to levetiracetam, 517 to topiramate, 512 to carbamazepine, 365 to gabapentin, 139 to oxcarbazepine and 80 to phenobarbital. Exposure to valproic acid was associated with 8 specific types of MCMs (e.g. spina bifida, OR=19.4[8.6-43.5]) and exposure to topiramate was associated with an increased risk of cleft lip (6.8[1.4-20.0]). We identified three other signals. We found no significant association for lamotrigine, levetiracetam, carbamazepine, oxcarbazepine and gabapentin. Conclusions: These results confirm the teratogenicity of valproic acid and topiramate. Because of the small numbers of cases and possible confounding, the other three signals should be interpreted with appropriate caution.
Brain Safe: Consumer Intervention to Reduce Exposure to Drugs Linked to Alzheimer's Disease
ClinicalTrials.gov study NCT04121858. IPD Sharing: NO. Countries: 1. Publications: 2.
Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment Population
ClinicalTrials.gov study NCT00787423. IPD Sharing: NO. Countries: 1. Publications: 1.
Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
ClinicalTrials.gov study NCT01995981. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development
ClinicalTrials.gov study NCT01020669. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
ClinicalTrials.gov study NCT04694586. IPD Sharing: NO. Countries: 1. Publications: 1.
Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation
ClinicalTrials.gov study NCT01316549. IPD Sharing: NO. Countries: 1. Publications: 1.
A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in S
ClinicalTrials.gov study NCT02964104. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Optimizing HIV Pre-exposure Prophylaxis (PrEP) Among Women Who Use Drugs in Tanzania
ClinicalTrials.gov study NCT06835751. IPD Sharing: YES. Countries: 1. Publications: 1.
Hypnotic Medications and Memory: Effect of Drug Exposure During the Night
ClinicalTrials.gov study NCT01159652. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Tolerance to Sevoflurane in Children Undergoing Repeated Drug Exposure
ClinicalTrials.gov study NCT04188782. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.